Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Filtros adicionais











País/Região como assunto
Intervalo de ano
1.
Med Clin (Barc) ; 2019 May 03.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31060878

RESUMO

BACKGROUND AND OBJECTIVES: Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine. MATERIAL AND METHODS: Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied. RESULTS: 253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054). CONCLUSIONS: Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.

2.
Clin Exp Rheumatol ; 35(5): 752-765, 2017 Sep-Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28516869

RESUMO

OBJECTIVES: Inflammatory arthritis needs infectious disease screening before starting a biologic agent, however, few data are known about migrant patients, who represent a peculiar population which requires a multidisciplinary approach among international health specialists and should also be considered by health authorities. For this reason, the Italian and Spanish Societies of Rheumatology (SIR and SER) and Tropical Medicine (SIMET and SEMTSI) promoted a multidisciplinary task force in order to produce specific recommendations about screening and advices to be considered in migrant patients with inflammatory arthritis candidate to receive biological therapy, according to their geographical origin. METHODS: The experts provided a prioritised list of research questions and the eligible spectrum of inflammatory arthritis, biologic drugs and infectious disease were defined in order to perform a systematic literature review. A search was made in Medline, Embase and Cochrane library, updated to March 2015. Ubiquitous infections and HBV, HCV, HIV and tuberculosis that are already considered in national and international recommendations, were not included. The strength of each recommendation was determined. RESULTS: The task force members agreed on 7 overarching principles. The risk of reactivation of selected potentially latent infectious disease was addressed in migrants with inflammatory arthritis candidates for biologics was considered and 15 potentially relevant infections were identified. CONCLUSIONS: Fifteen disease-specific recommendations were formulated on the basis of high level of agreement among the experts panel.


Assuntos
Comitês Consultivos , Artrite Reumatoide/tratamento farmacológico , Produtos Biológicos/uso terapêutico , Doenças Transmissíveis/diagnóstico , Emigrantes e Imigrantes , Emigração e Imigração , Infectologia/normas , Programas de Rastreamento/normas , Reumatologia/normas , Sociedades Médicas , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/etnologia , Produtos Biológicos/efeitos adversos , Doenças Transmissíveis/etnologia , Consenso , Medicina Baseada em Evidências/normas , Humanos , Itália/epidemiologia , Programas de Rastreamento/métodos , Valor Preditivo dos Testes , Medição de Risco , Fatores de Risco , Espanha/epidemiologia
3.
Medicine (Baltimore) ; 95(9): e2891, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26945378

RESUMO

The aim of the study was to profile those patients included in the RELESSER registry with histologically proven renal involvement in order to better understand the current state of lupus nephritis (LN) in Spain. RELESSER-TRANS is a multicenter cross-sectional registry with an analytical component. Information was collected from the medical records of patients with systemic lupus erythematosus who were followed at participating rheumatology units. A total of 359 variables including demographic data, clinical manifestations, disease activity, severity, comorbidities, LN outcome, treatments, and mortality were recorded. Only patients with a histological confirmation of LN were included. We performed a descriptive analysis, chi-square or Student's t tests according to the type of variable and its relationship with LN. Odds ratio and confidence intervals were calculated by using simple logistic regression. LN was histologically confirmed in 1092/3575 patients (30.5%). Most patients were female (85.7%), Caucasian (90.2%), and the mean age at LN diagnosis was 28.4 ±â€Š12.7 years. The risk for LN development was higher in men (M/F:47.85/30.91%, P < 0.001), in younger individuals (P < 0.001), and in Hispanics (P = 0.03). Complete response to treatment was achieved in 68.3% of patients; 10.35% developed ESRD, which required a kidney transplant in 45% of such cases. The older the patient, the greater was the likelihood of complete response (P < 0.001). Recurrences were associated with persistent lupus activity at the time of the last visit (P < 0.001) and with ESRD (P < 0.001). Thrombotic microangiopathy was a risk factor for ESRD (P = 0.04), as for the necessity of dialysis (P = 0.01) or renal transplantation (P = 0.03). LN itself was a poor prognostic risk factor of mortality (OR 2.4 [1.81-3.22], P < 0.001). Patients receiving antimalarials had a significantly lower risk of developing LN (P < 0.001) and ESRD (P < 0.001), and responded better to specific treatments for LN (P = 0.014). More than two-thirds of the patients with LN from a wide European cohort achieved a complete response to treatment. The presence of positive anti-Sm antibodies was associated with a higher frequency of LN and a decreased rate of complete response to treatment. The use of antimalarials reduced both the risk of developing renal disease and its severity, and contributed to attaining a complete renal response.


Assuntos
Nefrite Lúpica/epidemiologia , Sistema de Registros , Adolescente , Adulto , Feminino , Humanos , Nefrite Lúpica/terapia , Masculino , Recidiva , Estudos Retrospectivos , Reumatologia , Espanha/epidemiologia , Adulto Jovem
4.
Medicine (Baltimore) ; 94(1): e267, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25569641

RESUMO

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement and pronounced racial and ethnic heterogeneity. The aims of the present work were (1) to describe the cumulative clinical characteristics of those patients included in the Spanish Rheumatology Society SLE Registry (RELESSER), focusing on the differences between patients who fulfilled the 1997 ACR-SLE criteria versus those with less than 4 criteria (hereafter designated as incomplete SLE (iSLE)) and (2) to compare SLE patient characteristics with those documented in other multicentric SLE registries.RELESSER is a multicenter hospital-based registry, with a collection of data from a large, representative sample of adult patients with SLE (1997 ACR criteria) seen at Spanish rheumatology departments. The registry includes demographic data, comprehensive descriptions of clinical manifestations, as well as information about disease activity and severity, cumulative damage, comorbidities, treatments and mortality, using variables with highly standardized definitions.A total of 4.024 SLE patients (91% with ≥4 ACR criteria) were included. Ninety percent were women with a mean age at diagnosis of 35.4 years and a median duration of disease of 11.0 years. As expected, most SLE manifestations were more frequent in SLE patients than in iSLE ones and every one of the ACR criteria was also associated with SLE condition; this was particularly true of malar rash, oral ulcers and renal disorder. The analysis-adjusted by gender, age at diagnosis, and disease duration-revealed that higher disease activity, damage and SLE severity index are associated with SLE [OR: 1.14; 95% CI: 1.08-1.20 (P < 0.001); 1.29; 95% CI: 1.15-1.44 (P < 0.001); and 2.10; 95% CI: 1.83-2.42 (P < 0.001), respectively]. These results support the hypothesis that iSLE behaves as a relative stable and mild disease. SLE patients from the RELESSER register do not appear to differ substantially from other Caucasian populations and although activity [median SELENA-SLEDA: 2 (IQ: 0-4)], damage [median SLICC/ACR/DI: 1 (IQ: 0-2)], and severity [median KATZ index: 2 (IQ: 1-3)] scores were low, 1 of every 4 deaths was due to SLE activity.RELESSER represents the largest European SLE registry established to date, providing comprehensive, reliable and updated information on SLE in the southern European population.


Assuntos
Lúpus Eritematoso Sistêmico/epidemiologia , Sistema de Registros , Adulto , Estudos Transversais , Feminino , Humanos , Masculino , Espanha/epidemiologia
5.
Rheumatology (Oxford) ; 52(2): 376-81, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23065319

RESUMO

OBJECTIVE: To compare the carotid intima-media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls. METHODS: Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated radiofrequency-based US by the same investigator at each centre. RESULTS: Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with synthetic and biologic DMARDs. There were no significant differences between the RA patients and controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers among RA patients treated with synthetic and biologic DMARDs (P = 0.036). Disease duration and duration of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and biologic DMARDs (P < 0.0005). The mean CCA-IMT was significantly greater in RA patients treated only with synthetic DMARDs than in controls [591.4 (98.6) vs 562.1 (85.8); P = 0.035] and in RA patients treated with synthetic and biologic DMARDs [591.4 (98.6) vs 558.8 (95.3); P = 0.040). There was no significant difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and controls (P = 0.997). CONCLUSION: Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate between RA patients treated with synthetic DMARDs vs RA patients treated with synthetic and biologic DMARDs.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/diagnóstico por imagem , Produtos Biológicos/uso terapêutico , Artéria Carótida Primitiva/diagnóstico por imagem , Espessura Intima-Media Carotídea , Adulto , Artrite Reumatoide/tratamento farmacológico , Estudos de Casos e Controles , Estudos Transversais , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Túnica Íntima/diagnóstico por imagem , Ultrassonografia/métodos
6.
Rheumatol Int ; 31(12): 1549-54, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20490803

RESUMO

To assess the diagnostic correlation between primary care physicians and rheumatologists in patients with temporary work disability (TWD) related to musculoskeletal diseases (MSD). All patients with TWD related to MSDs in three health districts of Madrid, Spain, were randomized into standard care by primary care physicians (PCP) or the intervention group by rheumatologists. According to the cause, every TWD episode was classified into 11 syndrome categories. To examine the concordance between the rheumatologist and the referring PCP for each diagnosis, we used Kappa statistic (k) and 95% confidence interval (CI). A total of 3,311 (62.8%) were analyzed, 49.8% women, with a mean age of 41 years ± 12 years, 93.3% were general workers. The agreement between PCP and rheumatologists in all the diagnoses was moderated (k = 0.62). The highest agreement was found in tendonitis (k = 0.81, 95% CI 0.78-0.84), and microcrystalline and undifferentiated arthritis (k = 0.72, 95% CI 0.68-0.77). Lowest agreements were found for peripheral osteoarthritis (k = 0. 48 95% CI 0.38-0.57), knee pain (k = 0.40, 95% CI 0.29-0.52), and muscular pain (k = 0.15, 95% CI 0.10-0.20) Although the global agreement on the musculoskeletal diagnosis between PCPs and rheumatologist in patients with TWD related to MSDs was reasonable, the correlation for peripheral osteoarthritis, knee pain, and muscular pain was low.


Assuntos
Avaliação da Deficiência , Doenças Musculoesqueléticas/diagnóstico , Médicos de Atenção Primária , Reumatologia , Adulto , Artrite/diagnóstico , Emprego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor , Tendinopatia/diagnóstico , Recursos Humanos
7.
Arthritis Rheum ; 57(1): 116-24, 2007 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-17266071

RESUMO

OBJECTIVE: To evaluate the sensitivity to change of power Doppler ultrasound (PDUS) assessment of joint inflammation and the predictive value of PDUS parameters in disease activity and radiologic outcome in patients with early rheumatoid arthritis (RA). METHODS: Forty-two patients with early RA who started therapy with disease-modifying antirheumatic drugs underwent blinded sequential clinical, laboratory, and ultrasound assessment at baseline, 3 months, 6 months, and 1 year and radiographic assessment at baseline and 1 year. For each patient, 28-joint Disease Activity Score (DAS28) was recorded at each visit. The presence of synovitis was investigated in 28 joints using gray-scale ultrasonography and intraarticular power Doppler signal. Active synovitis was defined as intraarticular synovitis detected with power Doppler signal. The ultrasound joint count for active synovitis and an overall joint index for power Doppler signal were calculated. Sensitivity to change of PDUS variables was assessed by estimating the smallest detectable difference (SDD) from the intraobserver variability. RESULTS: The SDD for ultrasound joint count for active synovitis and ultrasound joint index for power Doppler signal was lower than mean changes from baseline to 3 months, 6 months, and 1 year. Time-integrated values of PDUS parameters demonstrated a highly significant correlation with DAS28 after 1 year (r = 0.63, P < 0.001) and a stronger correlation with radiographic progression (r = 0.59-0.66, P < 0.001) than clinical and laboratory parameters (r < 0.5). CONCLUSION: PDUS is a sensitive and reliable method for longitudinal assessment of inflammatory activity in early RA. PDUS findings may have a predictive value in disease activity and radiographic outcome.


Assuntos
Artrite Reumatoide/diagnóstico por imagem , Articulações/diagnóstico por imagem , Ultrassonografia Doppler/métodos , Doença Aguda , Adulto , Idoso , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/fisiopatologia , Artrografia/métodos , Progressão da Doença , Feminino , Humanos , Articulações/fisiopatologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Sinovite/diagnóstico por imagem , Sinovite/tratamento farmacológico , Sinovite/fisiopatologia
8.
Med. clín (Ed. impr.) ; 114(9): 326-330, mar. 2000.
Artigo em Espanhol | IBECS | ID: ibc-6315

RESUMO

Fundamento: Se ha descrito una elevada frecuencia de deficiencia de vitamina D en la población senil en Europa, pero hay poca información sobre la prevalencia de deficiencia de esta vitamina en la población posmenopáusica en países mediterráneos. El objetivo de este estudio ha sido valorar su prevalencia en mujeres posmenopáusicas procedentes de una consulta reumatológica y evaluar la vitamina D durante un año tras dos pautas de tratamiento. Pacientes y métodos: Se valoró el 25(OH)D3 (calcidiol) sérico en 171 mujeres posmenopáusicas (111 con osteoporosis y 60 sin ella) procedentes de una consulta de reumatología en Madrid. Un grupo seleccionado de 83 mujeres con concentraciones de calcidiol inferiores a 10 ng/ml fue aleatorizado en dos grupos: al grupo I se le prescribieron 800 U/día de vitamina D3 y 1 g/día de calcio, y al grupo II una dosis de 80.000 U de vitamina D3 en forma de calcidiol, seguida de 800 U/día de vitamina D3 junto a 1 g/día de calcio. El calcidiol se cuantificó por RIA en situación basal y a los 3, 6 y 12 meses de tratamiento. Se establecieron tres puntos de corte: 10, 15 y 20 ng/ml de calcidiol para calcular la prevalencia de deficiencia. Resultados: Los porcentajes de mujeres con deficiencia de vitamina D considerada como calcidiol < 10, < 15 o < 20 ng/ml fueron: el 35,3, el 64,1 y el 87,1 por ciento, respectivamente. Tras el tratamiento el calcidiol en el grupo II fue mayor que en el grupo I a los 3 meses. El porcentaje de mujeres con concentraciones superiores a 10 y 15 ng/ml fue mayor en el grupo II que en el grupo I. Sin embargo, los valores de calcidiol se igualaron a los 6 y 12 meses. Conclusión: Se observa una elevada prevalencia de deficiencia de vitamina D en un grupo de mujeres posmenopáusicas que acudieron a una consulta reumatológica en Madrid. Ambas pautas de administración de vitamina D parecen ser insuficientes para mantener las concentraciones adecuadas de calcidiol sérico. Debería considerarse una pauta de 80.000 U dos veces al año. (AU)


Assuntos
Pessoa de Meia-Idade , Idoso , Masculino , Feminino , Humanos , Pós-Menopausa , Espanha , Deficiência de Vitamina D , Vitamina D , Prevalência , Fraturas da Coluna Vertebral , Incidência , Distribuição por Sexo , Reumatologia , Esquema de Medicação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA